Overview

• Takeda expects an impairment of about 58 billion yen (roughly $394 million) tied to its gamma-delta cell therapy technology, with further impacts to be detailed in Oct. 30 results.
• The company plans to partner out its platform technologies and certain clinic-ready programs and currently has no active cell therapy clinical trials.
• Near-term R&D focus shifts to antibody-drug conjugates, biologics and small molecules judged to deliver therapies faster and at greater scale.
• The decision follows years of investment as a later entrant to cell therapy and a 2024 restructuring that had already pared back programs in oncology.
• Pharmaceutical Technology reports the exit will result in 137 job losses at Takeda’s Massachusetts R&D site.